[HTML][HTML] Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
I Okamoto, S Morita, N Tashiro, F Imamura, A Inoue… - Lung Cancer, 2018 - Elsevier
Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
[HTML][HTML] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line …
E Bria, M Milella, F Cuppone, S Novello, A Ceribelli… - Annals of oncology, 2011 - Elsevier
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
DH Koo, K Kim, CM Choi, DH Lee, JC Lee… - Cancer chemotherapy …, 2015 - Springer
Purpose Although epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs)
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a …
N Zhao, X Zhang, H Yan, J Yang, Y Wu - Lung Cancer, 2014 - Elsevier
Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR …
I Okamoto, T Mitsudomi, K Nakagawa… - … advances in medical …, 2010 - journals.sagepub.com
Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal
growth factor receptor (EGFR), were the first molecularly targeted agents to become …
growth factor receptor (EGFR), were the first molecularly targeted agents to become …
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for …
A Inoue, K Yoshida, S Morita, F Imamura… - Japanese journal of …, 2016 - academic.oup.com
Abstract Background The Japan Guidelines of Lung Cancer Therapy recommend epidermal
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …
EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study
W Schuette, P Schirmacher, WEE Eberhardt… - … , biomarkers & prevention, 2015 - AACR
Introduction: EGFR mutations confer sensitivity to EGFR tyrosine kinase inhibitors (TKI) in
advanced non–small cell lung cancer (NSCLC). We investigated the clinicopathologic …
advanced non–small cell lung cancer (NSCLC). We investigated the clinicopathologic …